Close Menu

NEW YORK – William Blair Thursday initiated coverage of Aspira Women's Health with an Outperform rating and a price target of $3.33 per share and coverage of DermTech with a rating of Outperform and a price target of $11.97 per share.

Aspira, formerly known as Vermillion, develops diagnostics in the women's health space. Its lead product, OVA1, is a proteomic test that is intended to help doctors assess whether women undergoing surgery for a pelvic mass should have that surgery done by a gynecologic oncologist.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.